{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096627","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.464083+00:00","generated_at":"2026-05-31T09:23:04.529488+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Eliem Therapeutics Q2 net loss $54.9M; completed Tenet Medicines acquisition and $120M financing","bullets":["Completed acquisition of Tenet Medicines and concurrent $120M private placement in June 2024.","Cash and equivalents $223.1M as of June 30, expected to fund operations into 2027.","Net loss of $54.9M for Q2 2024 vs $5.2M in Q2 2023, largely due to $51.7M acquired IP R&D expense.","Lead product budoprutug (anti-CD19) targets autoimmune diseases including lupus and immune thrombocytopenia.","Appointed Aoife Brennan as CEO and Jan Hillson as Senior Clinical Advisor; added to Russell 2000 index."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096627","json":"https://secwatch.observer/filing/0000950170-24-096627.json","markdown":"https://secwatch.observer/filing/0000950170-24-096627.md","text":"https://secwatch.observer/filing/0000950170-24-096627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017024096627/0000950170-24-096627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017024096627/elym-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:23:04.529488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}